The Cutaneous Connection: Episode 30- Impact of the JAK Inhibitor Approval Delays

Mark Lebwohl, MD, takes a deep dive in the recent delay in approval for multiple JAK inhibitor drugs for treatment of inflammatory skin conditions such as psoriasis and atopic dermatitis. He also discusses the impact of the delay, as well as the benefits of JAK inhibitors for inflammatory skin diseases, and an outlook for the future of this drug class.

Related Videos

Related Content

Advertisement

Biologic Therapy Linked to Increased Density of Demodex Mites and Prevalence of Demodicosis in Patients With Psoriasis vs Controls

Article

The Cutaneous Connection: Make Data-Driven Decisions For Personalized AD Treatment

Podcast

US Central and European Commands Should Revisit Disallowance of Systemic Treatments for Deployed Individuals With Psoriasis, Eczema, Paper Argues

Article

The Cutaneous Connection: Splish, Splash, AD Management Starts in the Bath

Podcast

ASLAN Announces Positive Phase 2 Results of Eblasakimab in Dupilumab-Treated Patients With AD

Article

LC-OCT Demonstrates Potential For Rapid, Effective Visualization of Inflammatory Conditions Across Skin Types

Article

Related Content

Advertisement

Biologic Therapy Linked to Increased Density of Demodex Mites and Prevalence of Demodicosis in Patients With Psoriasis vs Controls

Article

The Cutaneous Connection: Make Data-Driven Decisions For Personalized AD Treatment

Podcast

US Central and European Commands Should Revisit Disallowance of Systemic Treatments for Deployed Individuals With Psoriasis, Eczema, Paper Argues

Article

The Cutaneous Connection: Splish, Splash, AD Management Starts in the Bath

Podcast

ASLAN Announces Positive Phase 2 Results of Eblasakimab in Dupilumab-Treated Patients With AD

Article

LC-OCT Demonstrates Potential For Rapid, Effective Visualization of Inflammatory Conditions Across Skin Types

Article